Christian Chavy, MBA.  Chairman of the Board

christianMr. Chavy is the former CEO of Stallergenes, a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. Christian was previously President of the Worldwide Business Operations at ACTELION Pharmaceuticals Ltd. and member of the Executive Committee. At ACTELION he has also held the positions of President, Head of Europe, Latin America, Middle East and Africa. Prior to joining ACTELION, he was the vice-president, Head of Global Therapeutic Area Reproductive Health at Serono International and Managing Director of Serono France.

He spent five years with Rhône Poulenc Rorer as Managing Director of Rorer France and President of RPR Canada Inc. for both Ethical and OTC activities. He also has held Marketing positions at Bristol-Myers France, Smith-Kline and Merck Sharp & Dhome.

Mr. Chavy is graduate from Ecole des Sciences Economiques et Commerciales (ESSEC) and holds a Master Degree of Business Management from Institut de Contrôle de Gestion in Paris (ICG).

Mr. Chavy is Chairman of the board of IXALTIS.

Dr. Philippe Lluel

Dr. Lluel obtained a Ph. D. degree in Pharmacology from the Pierre et Marie Curie University (Paris, France) and a Master degree in Biology and Pharmacology of Ageing. Before founding UROsphere, he spent over 11 years in pharmaceutical companies in drug discovery in the field of experimental urology. Throughout his career he worked closely with various groups charged with development, regulatory affairs and research. His expertise covers the fields of benign prostatic hyperplasia, urinary incontinence, overactive bladder and aging.

Dr. Lluel, in addition to being a board member, also contributes as scientific advisor for IXALTIS.

Mario Caria

Mario Caria is International Director and Senior Partner at Sofimac Partners France. He joined Sofimac in 2007. After having started and managed Spin Off, Start Up and Business in in clinical diagnostic,
medical devices and biotech, he launched Venture Capital funds dedicated to Healthcare, seed and growth. He has been Board Member of numerous companies and currently seats in Boards among which Advanced Perfusion Diagnostic SA, Fine-Heart SA, Centervue SpA.
Previously an Entrepreneur and formerly an Academic and Researcher at CERN, Geneva, he held Chairs in Medical Biophysics and had been teaching Health Technology Assesment in France and Italy.

He was Steering Board Member at several initiatives of the European Commission in Bruxelles. Hepublished over 150 papers and 4 books. He holds EMBA from University of Basel, Switzerland and Harvard Business School Certificate.

In IXALTIS he brings his sound Corporate knowledge and International network

Jean-Michel Petit

petitJean-Michel heads the venture capital practice of IRDI Gestion where he manages the seed fund IRDInov investing in start-ups located in the South-West of France.  He serves on the boards of several portfolio companies such as Gamamabs, Fineheart, EnobraQ, Telecom Design, Ademtech and LDL Technology.  Before joining IRDI Gestion, he spent 4 years with CDP capital’s Life Science venture capital team based first in Montreal and then in Paris.  In this position, he made a range of international investments mostly in the US.  Before joining CDP capital , he worked for a regional fund based in Montreal.
Jean-Michel graduated from Chimie ParisTech and holds and MSc degree from Montreal university and and MBA from McGill.

Paolo Siviero

paoloFund Manager of Principia III, a specialized venture capital fund targeting biotech and medical technology companies. Principia III, the third venture capital fund set up by Principia SGR, become the largest Italian strategic investor in a sector widely expected to be the major driver in knowledge-based economies after the information technology revolution.

Mr Siviero worked for the Italian Medicines Agency (AIFA) from 2007 to 2014 where he led the “Economic Strategy and Pharmaceutical Policy” Unit, responsible for the sustainability of the National Health System with respect to the pharmaceutical sector. During this time, Mr. Siviero was also appointed as :

– Italian Alternate Member of the European Medicines Agency (EMA) Management Board.
– President of Medicine Evaluation Committee (MEDEV), a group that represent the major
European Payers.
– Secretary of the Technical and Scientific Committee of the Italian Medicines Agency
– Secretary of the Pricing and Reimbursement Committee of the Italian Medicines Agency.
– AIFA’s Representative at the European Networking of the Competent Authorities for Pricing and Reimbursement of Pharmaceutical.
– Appointed by the Italian Minister of Health as National Expert at the European Network for HTA.

During his career, Mr. Siviero has cooperated several years with the Italian National Research Council, regarding the development of issues such as the technological transfer, knowledge management and the economical valorization of results obtained through researches.

Dr. Roberto Gradnik, CEO

Roberto Gradnik

Trained as a physician, Roberto Gradnik has more than 25 years’ experience in the pharmaceutical and biotechnology sector. After holding various positions with the Knoll Group (a subsidiary of the BASF Group), including that of Vice-President International Marketing Cardiovascular, he joined the Serono Group in 1999 as Italy’s General Manager and Head of Southern European Subsidiaries. He was then appointed Executive Vice-President for Europe, in charge of all European markets, and a member of the Executive Committee. He continued in the same position for Merck Serono after the acquisition of Serono by Merck AG. More recently, he was appointed Executive Vice-President, Global Business Unit for Neurodegenerative Diseases for Merck Serono. Since January 1st, 2012 until March 31 st , 2014 he was Chief Executive Officer of Stallergenes, a European biopharmaceutical company specialized in the treatment of severe respiratory allergies with allergen immunotherapy. Roberto Gradnik is President of EBE (European Biopharmaceutical Enterprises).

Hasnaa Hafid (as observer). Associate at IXO Private Equity

HHIXO Private Equity is the most important independent private equity General Partner in France dedicated to small, small-mid cap buyout and growth transactions. It manages a 550 €m asset portfolio of capital-investment.

Based in Toulouse, Marseille, IXO Private Equity is meeting the equity needs for the best companies in the Great South of France (Southern West, Southern East) and Rhône-Alpes by investments between 1 et 15 €m.

Our teams long term expertise in this field (Growth Capital, MBO, OBO, Spin-Off, Build-up…) and the focus of the Board of Experts are the major factors contributing to our success. A proprietary deal flow has been developed which help us to target niche markets, local know-how and international exposure companies without any hard competitions. The result is a very long and robust track record in this extented period of time.

More information at : www.ixope.fr